{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:51:15Z","timestamp":1793659875386,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.esmoop.2024.104088","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:32:24Z","timestamp":1736058744000},"page":"104088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers"],"prefix":"10.1016","volume":"10","author":[{"given":"J.-Y.","family":"Blay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Swalduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Avrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Assaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bourbotte-Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dutour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Heudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.104088_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929572","article-title":"The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment","volume":"13","author":"Aguilar-Cazares","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.esmoop.2024.104088_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5306\/wjco.v5.i3.197","article-title":"Paraneoplastic syndromes associated with lung cancer","volume":"5","author":"Kanaji","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104088_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2024.104088_bib4","first-page":"3317","article-title":"Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma","volume":"52","author":"Blay","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104088_bib5","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V82.7.2038.2038","article-title":"Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction","volume":"82","author":"Melhem","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2024.104088_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R","article-title":"Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma","volume":"72","author":"Blay","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2024.104088_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1006\/gyno.1999.5589","article-title":"Inflammatory malignant fibrous histiocytoma of the ovary producing interleukin-6: a case report","volume":"75","author":"Yamakawa","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2024.104088_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3816\/CCC.2008.n.044","article-title":"Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer","volume":"7","author":"Sharma","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2024.104088_bib9","first-page":"55","article-title":"The role of interleukin-6 in malignant mesothelioma","volume":"4","author":"Abdul Rahim","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104088_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/neup.12877","article-title":"Systemic inflammation caused by an intracranial mesenchymal tumor with a EWSR1::CREM fusion presenting associated with IL-6\/STAT3 signaling","volume":"43","author":"Hojo","year":"2023","journal-title":"Neuropathology"},{"key":"10.1016\/j.esmoop.2024.104088_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/mco.2023.2704","article-title":"C-reactive protein and related predictors in soft tissue sarcoma (Review)","volume":"20","author":"Nakamura","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104088_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/cancers15051573","article-title":"The prognostic value of the serum level of C-reactive protein for survival of children with Ewing\u2019s sarcoma","volume":"15","author":"Errani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.104088_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103806","article-title":"Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"179","author":"Rebuzzi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2024.104088_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jcsm.12912","article-title":"Caledonian Cachexia Collaborative. A systematic review examining the relationship between cytokines and cachexia in incurable cancer","volume":"13","author":"Paval","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.esmoop.2024.104088_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","article-title":"IL-6 and related cytokines as the critical lynchpins between inflammation and cancer","volume":"26","author":"Taniguchi","year":"2014","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104088_bib16","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104088_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1093722","article-title":"Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis","volume":"5","author":"Lippitz","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2024.104088_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1411569","article-title":"Interleukin-6 and its receptor: a paradigm for cytokines","volume":"258","author":"Kishimoto","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2024.104088_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2024.104088_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2024.104088_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104088_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2141.2000.02093.x","article-title":"A\u00a0combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma","volume":"109","author":"Moreau","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104088_bib23","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V86.8.3123.3123","article-title":"Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments","volume":"86","author":"Lu","year":"1995","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104088_bib24","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood.V84.8.2472.2472","article-title":"Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms","volume":"84","author":"Emilie","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104088_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108530","article-title":"Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: an addition for existing risk classification systems?","volume":"50","author":"van der Laan","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.esmoop.2024.104088_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/07357900500524322","article-title":"Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin","volume":"24","author":"Diament","year":"2006","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104088_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000756","article-title":"Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma","volume":"5","author":"Eberst","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104088_bib28","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpainsymman.2013.01.009","article-title":"Favorable responses to tocilizumab in two patients with cancer-related cachexia","volume":"46","author":"Hirata","year":"2013","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.esmoop.2024.104088_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/ijerph21020189","article-title":"Consore: a powerful federated data mining tool driving a French research network to accelerate cancer research","volume":"21","author":"Gu\u00e9rin","year":"2024","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104088_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000415","article-title":"From data strategy to implementation to advance cancer research and cancer care: a French comprehensive cancer center experience","volume":"2","author":"Heudel","year":"2023","journal-title":"PLOS Digit Health"},{"key":"10.1016\/j.esmoop.2024.104088_bib31","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s10147-021-01963-3","article-title":"Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center","volume":"26","author":"Heudel","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104088_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.esmoop.2024.104088_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.esmoop.2024.104088_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-3-031-59815-9_37","article-title":"IL-6 blockade in cytokine storm syndromes","volume":"1448","author":"Barrett","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.esmoop.2024.104088_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2249.1994.tb06145.x","article-title":"Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6","volume":"98","author":"Legouffe","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.esmoop.2024.104088_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jnci\/86.3.238","article-title":"Local production of interleukin 6 by renal adenocarcinoma in\u00a0vivo","volume":"86","author":"Blay","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.104088_bib37","article-title":"Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing","author":"Zewdu","year":"2024","journal-title":"bioRxiv"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:12:14Z","timestamp":1740651134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2059702924018581"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104088","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104088"}}